Full Text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

COVID-19 affects persons living with HIV (PLWH) both directly (via morbidity/mortality) and indirectly (via disruption of HIV care). From July–November 2020, an online survey was conducted to investigate the psychosocial well-being of PLWH and changes in HIV care during the second semester of the COVID-19 outbreak. Data were collected on the socio-demographic characteristics of PLWH, their psychosocial well-being, impact of COVID-19 preventive measures on their daily routines and HIV follow-up. Of the 247 responses analyzed (mean age: 44.5 ± 13.2 years; 73.7% male), 67 (27.1%) and 69 (27.9%) respondents screened positive for anxiety (GAD-2 score ≥ 3) and depression (PHQ-2 score ≥ 3), respectively. HIV care had returned to pre-COVID-19 state for 48.6% PLWH, and 108 (43.7%) had no HIV follow-up during the past month. Over three quarters (76.1%) of respondents expressed willingness to receive the COVID-19 vaccine. Compared to previous findings in April 2020, substance use increased from 58.6% to 67.2% (p < 0.001). Our findings suggest that the well-being and medical follow-up of PLWH are still affected after almost a year into the COVID-19 outbreak. Remote HIV follow-up (telemedicine) with psychosocial support should be envisaged in the medium to long-term. Given that most PLWH accept COVID-19 vaccination, they may be prioritized for this intervention.

Details

Title
Follow-Up Survey of the Impact of COVID-19 on People Living with HIV during the Second Semester of the Pandemic
Author
Joseph Nelson Siewe Fodjo 1   VIAFID ORCID Logo  ; Edlaine Faria de Moura Villela 2   VIAFID ORCID Logo  ; Stijn Van Hees 1   VIAFID ORCID Logo  ; Vanholder, Pieter 3 ; Reyntiens, Patrick 4 ; Colebunders, Robert 1   VIAFID ORCID Logo 

 Global Health Institute, University of Antwerp, 2610 Wilrijk, Belgium; [email protected] (S.V.H.); [email protected] (R.C.) 
 Disease Control Coordination, State Health Department, São Paulo 01246000, Brazil; Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605050, Brazil; [email protected] 
 European AIDS Treatment Group, 1000 Brussels, Belgium; [email protected] 
 Sensoa, Flemish Expertise Centre for Sexual Health, 2060 Antwerp, Belgium; [email protected] 
First page
4635
Publication year
2021
Publication date
2021
Publisher
MDPI AG
ISSN
1661-7827
e-ISSN
1660-4601
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2528255142
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.